Ruo-Nan Yang

Ruo-Nan Yang

Auto-generated profile, based on publicly available information

Ruo-Nan Yang

Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Key Laboratory of Laboratory Medicine of Henan Province, Zhengzhou 450052, Henan, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2018 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
RYRuonan Yang
Ruonan Yang
NGNan Gao
Nan Gao
QCQian Chang
Qian Chang
XMXianchun Meng
Xianchun Meng
WWWanhai Wang
Wanhai Wang

14 November 2018 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
Nan GaoNan Gao
Nan Gao
RYRuo-Nan Yang
Ruo-Nan Yang
ZMZhen Meng
Zhen Meng
WWWanhai Wang
Wanhai Wang
The C-reactive protein/albumin ratio (CRP/Alb ratio) has been reported to have promising prognostic value in several cancers. The current meta-analysis was conducted to better define the prognostic value of CRP/Alb ratio in patients with NPC. The Web of Science, Embase, Cochrane Library databases and PubMed were searched up to February 25, 2018 for the information on CRP/Alb ratio and outcomes of NPC. Pooled hazard ratios (HRs) and corresponding 95% confidence intervals (95% CIs) were used to evaluate the association between CRP/Alb ratio and survival outcomes in NPC. A total of five studies with 5,533 patients with NPC were included. Pooled results showed that high CRP/Alb ratio was associated with poor overall survival (OS) (HR=1.51, 95% CI: 1.30-1.75, P <0.001) and poor distant metastasis-free survival (DMFS) (HR=1.23, 95% CI: 1.07-1.43, P =0.005). Subgroup analyses showed that patients with higher CRP/Alb ratio have worse OS in NPC. In conclusion, elevated CRP/Alb ratio was associated with worse prognosis in patients with NPC.